Lung neuroendocrine tumors (LNETs) are uncommon cancers, and there is a paucity of randomized evidence to guide practice. As a result, current guidelines from different neuroendocrine tumor societies vary considerably. There is a need to update and harmonize global consensus guidelines. This article reports the best practice guidelines produced by a collaboration between the Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society. We performed a formal endorsement and updating process of the 2015 European Neuroendocrine Tumor Society expert consensus article on LNET. A systematic review from January 2013 to October 2017 was conducted to procure the most recent evidence. The stepwise endorsement process involved experts from all major subspecialties, patients, and advocates. Guided by discussion of the most recent evidence, each statement from the European Neuroendocrine Tumor Society was either endorsed, modified, or removed. New consensus statements were added if appropriate. The search yielded 1109 new publications, of which 230 met the inclusion criteria. A total of 12 statements were endorsed, 22 statements were modified or updated, one was removed, and two were added. Critical answered questions for each topic in LNET were identified. Through the consensus process, guidelines for the management of patients with local and metastatic neuroendocrine tumors have been updated to include both recent evidence and practice changes relating to technological and definitional advances. The guidelines provide clear, evidence-based statements aimed at harmonizing the global approach to patients with LNETs, on the basis of the principles of person-centered and LNET-specific care. The importance of LNET-directed research and person-centered care throughout the diagnosis, treatment, and follow-up journey is emphasized along with directions for future collaborative research.

中文翻译：

---

肺神经内分泌肿瘤患者诊断和管理的 CommNETs/NANETS 指南：2015 年 ENETS 专家共识指南的国际合作认可和更新。

肺神经内分泌肿瘤 (LNET) 是罕见的癌症，缺乏随机证据来指导实践。因此，来自不同神经内分泌肿瘤学会的当前指南差异很大。需要更新和协调全球共识指南。本文报告了由英联邦神经内分泌肿瘤研究合作组织和北美神经内分泌肿瘤协会合作制定的最佳实践指南。我们对 2015 年欧洲神经内分泌肿瘤学会关于 LNET 的专家共识文章进行了正式认可和更新。进行了 2013 年 1 月至 2017 年 10 月的系统评价以获取最新证据。逐步认可过程涉及来自所有主要亚专业、患者和倡导者的专家。在对最新证据的讨论的指导下，欧洲神经内分泌肿瘤学会的每一份声明都得到了认可、修改或删除。如果合适，增加了新的共识声明。搜索产生了 1109 篇新出版物，其中 230 篇符合纳入标准。共通过12条，修改或更新22条，删除1条，新增2条。确定了 LNET 中每个主题的关键回答问题。通过共识过程，局部和转移性神经内分泌肿瘤患者的管理指南已更新，包括与技术和定义进步相关的最新证据和实践变化。该指南提供了明确的、基于证据的声明，旨在协调 LNET 患者的全球方法，基于以人为本和 LNET 特定护理的原则。LNET 导向的研究和以人为本的护理在整个诊断、治疗和随访过程中的重要性以及未来合作研究的方向得到了强调。